# Rhode Island Medicaid and GLP-1s: Weight-Loss Coverage Ended October 1, 2026

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-07

Canonical page: https://glpwatchdog.org/research/rhode-island-medicaid-glp1-coverage

> The fiscal 2027 budget removed GLP-1s prescribed solely for weight loss from Rhode Island Medicaid. The state's memo and the three health plans' rules show what survives: type 2 diabetes drugs, Wegovy for heart disease and MASH, and Zepbound for sleep apnea, under new criteria.

## Key points

- Since October 1, 2026, Rhode Island Medicaid has not paid for four GLP-1s prescribed solely for weight loss.
- Tufts Health RITogether end-dated those approvals to September 30, 2026.
- All three Medicaid plans keep Wegovy for heart disease and MASH and Zepbound for sleep apnea, under new criteria.
- Ozempic, Mounjaro and other diabetes GLP-1s continue with prior authorization.
- Anyone under 21 gets a medical necessity review.

No, not for weight loss anymore. On October 1, 2026, Rhode Island Medicaid stopped paying for Wegovy, Zepbound, Saxenda or Foundayo when weight loss is the only reason for the prescription.[1] It did not end all coverage: diabetes drugs continue with prior authorization, and Tufts Health RITogether, Neighborhood Health Plan and UnitedHealthcare all keep Wegovy for heart disease and MASH and Zepbound for sleep apnea.[3][15][16]

> **About this article.** This page reads the state’s August 2026 memo to providers, the enacted budget language, and the notice and criteria the three Medicaid health plans posted for October 1, 2026, as they stood on November 7, 2026. For the federal rule behind state choices, see [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy).

## What changed in Rhode Island Medicaid on October 1, 2026?

The state budget for fiscal 2027 authorized the health secretary to remove GLP-1 coverage, except when prescribed to treat type 2 diabetes.[2] Federal Medicaid law does not require states to cover weight-loss drugs, so this was the state’s call, as it was next door in [Connecticut, where a 2025 budget act removed a coverage mandate](https://glpwatchdog.org/research/connecticut-husky-glp1-coverage).[9] The American Diabetes Association read the budget the same way when it passed in June 2026, describing coverage limited to people with type 2 diabetes.[4] A statement from obesity groups, quoting the governor’s budget, put the savings at $6.3 million in general revenue and $20.3 million from all funds.[6]

The memo that implemented it is narrower. The Executive Office of Health and Human Services told providers on August 5, 2026 that coverage ends for four named drugs when weight loss is the sole reason they are prescribed.[1] It added that someone who needs one of them for another reason requires a new prior authorization with clinical documentation.[1] So the practical rule follows the memo, and the reason on the prescription now decides the outcome.

*Coverage after October 1, 2026, from the state memo, the Tufts Health RITogether notice of September 2026 and the criteria Neighborhood and UnitedHealthcare posted for that date.*

| Drug and use | Status | What is needed |
| --- | --- | --- |
| Wegovy, Zepbound, Saxenda or Foundayo, solely for weight loss | Not covered[1] | Under 21: reviewed for medical necessity[1] |
| Wegovy injection or tablet, heart risk | Covered at all three plans[3][15][16] | New prior authorization[1] |
| Wegovy injection, MASH with F2 to F3 fibrosis | Covered at all three plans[3][15][16] | New prior authorization[1] |
| Zepbound, moderate to severe sleep apnea with obesity | Covered at all three plans[3][15][16] | New prior authorization[1] |
| Ozempic, Mounjaro, Rybelsus, Trulicity, exenatide, liraglutide for type 2 diabetes | Covered[3] | Prior authorization; existing approvals stand[3] |

## Were people already on Wegovy or Zepbound allowed to stay on it?

We found no grandfathering in the documents. At Tufts Health RITogether, authorizations for weight loss were end-dated to September 30, 2026, and members were to be told by notice.[3] The state’s memo asked providers to review affected members’ treatment plans and discuss alternatives before the change.[1] We did not find a state count of how many members lost coverage.

Stopping has consequences a prescriber should plan for, so someone who lost coverage should raise it soon, not wait until the last pen. Our review of [what happens when you stop a GLP-1](https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1) covers weight regain and how it tends to unfold.

## Can you still get Wegovy for heart disease on Rhode Island Medicaid?

Yes, at all three plans, with a new prior authorization. Tufts’ notice keeps Wegovy, in injection or tablet form, for adults who have heart or artery disease and carry excess weight, which matches the labeled use.[3][10] Neighborhood and UnitedHealthcare posted criteria that took effect October 1. Both ask for a BMI of 27 or more, a past heart attack, stroke or symptomatic peripheral artery disease, standard heart drugs or a reason the patient cannot take them, a diet and activity plan, and no type 2 diabetes.[15][16] UnitedHealthcare also sets a minimum age of 45, excludes an A1C of 6.5% or more and class IV heart failure, and approves 12 months at a time; Neighborhood approves six months and points people with diabetes to Ozempic for heart protection.[16][15]

## Does Rhode Island Medicaid still cover Zepbound for sleep apnea?

Yes, at all three plans, for adults with obesity whose obstructive sleep apnea is moderate or severe (by comparison, [Kentucky Medicaid requires a three-month CPAP trial first](https://glpwatchdog.org/research/kentucky-medicaid-glp1-coverage)).[3][11] The two plans whose criteria we read ask for more than the label does, including a CPAP history or a reason CPAP cannot be used.[15][16]

*Plan criteria in effect October 1, 2026, from Neighborhood’s Medicaid policy reviewed August 2026 and UnitedHealthcare’s Rhode Island guidelines. We did not read Tufts’ detailed criteria.*

| Plan | Sleep apnea | MASH |
| --- | --- | --- |
| Neighborhood Health Plan | Apnea-hypopnea index of 15 or more on a sleep study; BMI 30, or 27 with a risk factor; CPAP for at least a month with sleepiness remaining; a monthly weight management program; prescribed with a weight loss clinic or dietitian and a sleep specialist’s notes; six months at first[15] | F2 to F3 confirmed in the past six months by elastography or a past biopsy; a GI or liver specialist; diet and activity; 12 months[15] |
| UnitedHealthcare | Sleep study with an index of 15 or more; BMI 30 or more in the past six months; a failed diet attempt; three months of positive airway pressure used at least 4 hours on 70% of nights, or not a candidate; no diabetes; a sleep, lung or ENT specialist; six months at first[16] | F2 or F3 by FibroScan, MRE or a biopsy in the past 12 months; lifestyle counseling; not started together with Rezdiffra; a GI or liver specialist; 12 months[16] |

The background on both uses is in [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) and [GLP-1s and fatty liver](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash). A prescriber should only request one of these routes when the diagnosis is real and documented.

## Does Rhode Island Medicaid still cover Ozempic and Mounjaro for diabetes?

Yes. Tufts says these drugs continue with prior authorization and that members who already have approval are not affected, though switching to a different one needs a new request.[3] The state told estimators in May 2026 that its fee-for-service rule asks for metformin or a TZD drug within the past 90 days, and Neighborhood’s current policy asks for three months of metformin at the highest tolerated dose, up to 2 grams a day, unless metformin is unsuitable.[5][17] Prediabetes is not a route: Neighborhood has no criteria for it.[5]

## What about children and teenagers?

Federal Medicaid rules for people under 21 still apply. The state says every request for that age group must be reviewed for medical necessity under Medicaid’s children’s benefit, known as EPSDT.[1] That is a review and not a promise of approval, and Tufts said its members would be assessed under a general criteria document posted October 1.[3]

## How do you appeal a denial from Rhode Island Medicaid?

- **Plan appeal.** Federal rules give managed care members 60 calendar days from the notice.[7]
- **State fair hearing.** After the plan decides, federal rules set a window of 90 to 120 calendar days, and your notice gives the date.[8]

An appeal cannot restore coverage the budget removed. It can succeed when a request for another use was wrongly treated as weight loss, or when the clinical record was incomplete. If your denial letter names a different deadline, follow the letter. Our guide on [getting a GLP-1 covered](https://glpwatchdog.org/research/how-to-get-a-glp1-covered-by-insurance) has more on what to send.

## What are the options after losing coverage?

Cash is the main path. Prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose up to $449 at higher doses for Lilly’s self-pay Zepbound.[12][13] Lilly’s savings card excludes government programs, so read each offer’s terms.[12] People also on Medicare may qualify for the Medicare GLP-1 Bridge through December 31, 2027, at a BMI of 35, or 30 with certain conditions.[14] The guide to the [lowest GLP-1 prices without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares the options, and [our national page on Medicaid and Zepbound](https://glpwatchdog.org/research/does-medicaid-cover-zepbound) tracks where other states stand.

## Frequently asked questions

### Does Rhode Island Medicaid cover Wegovy for weight loss?

No. The program ended that coverage on October 1, 2026, for Wegovy, Zepbound, Saxenda and Foundayo when weight loss is the only reason for the prescription. The state's budget for fiscal 2027 made the change. Members under 21 have their requests reviewed for medical necessity.

### Does Rhode Island Medicaid cover Zepbound?

Not for weight loss. All three Medicaid plans keep Zepbound for adults with obesity whose sleep apnea is moderate or severe, with a new prior authorization. Neighborhood and UnitedHealthcare also want a sleep study with an index of 15 or more and a CPAP history or a reason CPAP cannot be used.

### Does Rhode Island Medicaid still cover Ozempic?

Yes, for type 2 diabetes with prior authorization. Tufts Health RITogether says members already approved are not affected. Switching to a different GLP-1 requires a new request. It is not covered for prediabetes or weight loss.

### Did people on Wegovy get to keep coverage after October 1, 2026?

The documents show no grandfathering for weight loss. One plan end-dated those approvals to September 30, 2026. Someone with another qualifying use, such as established heart disease, needs a new prior authorization request with clinical records.

### Can Medicare help if I lost Rhode Island Medicaid coverage for Wegovy?

Possibly, if you also have Medicare Part D. The Medicare GLP-1 Bridge runs through December 31, 2027, for people who meet its criteria, which start at a BMI of 35, or 30 with certain conditions. Medicaid-only members are not eligible.

## References

1. Rhode Island Executive Office of Health and Human Services Memorandum to RI Medicaid providers: GLP-1 State Budget Guidance, August 5, 2026. eohhs.ri.gov. 2026. https://eohhs.ri.gov/sites/g/files/xkgbur226/files/2026-08/2026%2008%2013%20GLP-1%20Change%202026%2010%2001.docx.pdf
2. Rhode Island General Assembly 2026 H 7127 Substitute A as amended: an act making appropriations for fiscal year 2027. rilegislature.gov. 2026. https://webserver.rilegislature.gov/BillText/BillText26/HouseText26/H7127Aaa.pdf
3. Point32Health Coverage of GLP-1s for Tufts Health RITogether members, September 2026. point32health.org. 2026. https://www.point32health.org/provider/coverage-glp-1s-tufts-health-ritogether-members-092026
4. American Diabetes Association The American Diabetes Association Expresses Concern Over Rhode Island's Decision to Eliminate Medicaid Coverage of Obesity Treatments, June 25, 2026. diabetes.org. 2026. https://diabetes.org/newsroom/press-releases/american-diabetes-association-expresses-concern-over-rhode-islands-decision
5. Rhode Island Executive Office of Health and Human Services May 2026 Caseload Estimating Conference: follow-up questions to April 27, 2026 testimony. rilegislature.gov. 2026. https://rilegislature.gov/Special/rcc/REC202605/04.30.26_Medicaid%20Follow%20Up_EOHHS_Updated.pdf
6. Obesity Action Coalition, The Obesity Society, American Society for Metabolic and Bariatric Surgery Statement for the record, April 9 Senate Finance Committee hearing on H 7127. rilegislature.gov. 2026. https://www.rilegislature.gov/senators/SenateComDocs/2026%20Finance/H7127%20Obesity%20Action%20Coalition%20+%20The%20Obesity%20Society%20+%20American%20Society%20for%20Metabolic%20and%20Bariatric%20Surgery%20-%20EOHHS%20budgets.pdf
7. Code of Federal Regulations 42 CFR §438.402: Statutory basis and general requirements (managed care appeals). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.402
8. Code of Federal Regulations 42 CFR §438.408: Resolution and notification of grievances and appeals. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.408
9. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8
10. Novo Nordisk WEGOVY (semaglutide): prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
11. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
12. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings
13. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
14. Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge: information for providers. cms.gov. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
15. Neighborhood Health Plan of Rhode Island GLP-1 and GLP-1/GIP Agonists (Non-Diabetes): Wegovy, Zepbound, Medicaid pharmacy policy reviewed August 2026. nhpri.org. 2026. https://www.nhpri.org/blobnhpri08e0944faa/wp-content/uploads/2026/10/Medicaid_GLP-1-Agonist-and-GLP-1GIP-Agonist-Non-Diabetes_Wegovy_-Zepbound_aCAS.20260817-4.pdf
16. UnitedHealthcare Community Plan of Rhode Island Clinical Pharmacy Guidelines: Wegovy and Zepbound prior authorization, effective October 1, 2026. uhcprovider.com. 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/commplan/ri/pharmacy/RI-Clinical-Pharmacy.pdf
17. Neighborhood Health Plan of Rhode Island GLP-1 and GIP/GLP-1 Agonists (diabetes): Ozempic, Rybelsus, Trulicity, Mounjaro, Medicaid pharmacy policy reviewed July 2026. nhpri.org. 2026. https://www.nhpri.org/blobnhpri08e0944faa/wp-content/uploads/2026/10/Medicaid_GLP_1_Agonists_GIP_GLP_1_diabetes_ozempic_Rybelsus_Trulicity_Mounjaro_aCAS_202600721-4.pdf

---

Cite as: GLP Watchdog, Nora Bissett, "Rhode Island Medicaid and GLP-1s: Weight-Loss Coverage Ended October 1, 2026", published 2026-11-07. https://glpwatchdog.org/research/rhode-island-medicaid-glp1-coverage

Canonical HTML page: https://glpwatchdog.org/research/rhode-island-medicaid-glp1-coverage

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.